Targeted therapy, as a new therapeutic method, plays an important role in the treatment of ESCC (32), such as targeting the metabolic vulnerability of SLC7A11-high cancer cells, glucose transporter type 1 biosynthesis, and glutathione induces NADPH dissipation, significant disulfide molecules accumulation, such as cysteine, and ROS accumulation, thereby inhibiting tumor growth and spread (33, 34). The gene discussed is SLC7A11; the disease is esophageal squamous cell carcinoma.